{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T15:11:13Z","timestamp":1782659473151,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T00:00:00Z","timestamp":1580083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004046","name":"Karen Elise Jensens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004046","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EClinicalMedicine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.eclinm.2020.100280","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T10:54:44Z","timestamp":1582109684000},"page":"100280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study"],"prefix":"10.1016","volume":"21","author":[{"given":"Kasper M\u00f8nsted","family":"Pedersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunus","family":"\u00c7olak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ellervik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Carl","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig Egil","family":"Bojesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge Gr\u00f8nne","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2020.100280_bib0001","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2020.100280_bib0002","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/102476","article-title":"MPNs as inflammatory diseases: the evidence, consequences, and perspectives","volume":"2015","author":"Hasselbalch","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.eclinm.2020.100280_bib0003","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2020.100280_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/670580","article-title":"Circulating cytokine levels as markers of inflammation in Philadelphia negative myeloproliferative neoplasms: diagnostic and prognostic interest","volume":"2015","author":"Mondet","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.eclinm.2020.100280_bib0005","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.eclinm.2020.100280_bib0006","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/101987","article-title":"The hen or the egg: inflammatory aspects of murine MPN models","volume":"2015","author":"Jutzi","year":"2015","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.eclinm.2020.100280_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183620","article-title":"Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development","volume":"12","author":"Andersen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2020.100280_bib0008","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/sim.3034","article-title":"Mendelian randomization: using genes as instruments for making causal inferences in epidemiology","volume":"27","author":"Lawlor","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.eclinm.2020.100280_bib0009","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/bioinformatics\/btv402","article-title":"LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants","volume":"31","author":"Machiela","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.eclinm.2020.100280_bib0010","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2020.100280_bib0011","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.bbadis.2014.05.018","article-title":"The interleukin-6 receptor Asp358Ala single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases","volume":"1842","author":"Garbers","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.eclinm.2020.100280_bib0012","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1200\/JCO.2015.63.3594","article-title":"Increased risk for other cancers in addition to breast cancer for CHEK2\u00d71100delC heterozygotes estimated from the Copenhagen general population study","volume":"34","author":"Naslund-Koch","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2020.100280_bib0013","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1126\/science.287.5462.2398","article-title":"Epidemiology. When an entire country is a cohort","volume":"287","author":"Frank","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.eclinm.2020.100280_bib0014","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish civil registration system as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.eclinm.2020.100280_bib0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/CLEP.S99462","article-title":"The Danish national chronic myeloid neoplasia registry","volume":"8","author":"Bak","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2020.100280_bib0016","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00008469-200506000-00002","article-title":"The data quality of haematological malignancy ICD-10 diagnoses in a population-based hospital discharge registry","volume":"14","author":"Norgaard","year":"2005","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.eclinm.2020.100280_bib0017","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.12099","article-title":"Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population","volume":"160","author":"Nielsen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.eclinm.2020.100280_bib0018","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","article-title":"JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate","volume":"99","author":"Nielsen","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.eclinm.2020.100280_bib0019","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","article-title":"Genetically elevated C-reactive protein and ischemic vascular disease","volume":"359","author":"Zacho","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2020.100280_bib0020","unstructured":"PhenoScanner v2: GWAS database[Available from: http:\/\/www.phenoscanner.medschl.cam.ac.uk\/. Accessed July 1st, 2019."},{"key":"10.1016\/j.eclinm.2020.100280_bib0021","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2020.100280_bib0022","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.eclinm.2020.100280_bib0023","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","article-title":"Role of interleukin-6 in cancer progression and therapeutic resistance","volume":"37","author":"Kumari","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.eclinm.2020.100280_bib0024","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(12)61246-X","article-title":"The interleukin 6 pathway and atherosclerosis","volume":"380","author":"Scheller","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2020.100280_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.1815","article-title":"Smoking is associated with increased risk of myeloproliferative neoplasms: a general population-based cohort study","author":"Pedersen","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.eclinm.2020.100280_bib0026","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3324\/haematol.2009.020412","article-title":"Autoimmunity and the risk of myeloproliferative neoplasms","volume":"95","author":"Kristinsson","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.eclinm.2020.100280_bib0027","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2020.100280_bib0028","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ije\/dyw088","article-title":"Selecting instruments for Mendelian randomization in the wake of genome-wide association studies","volume":"45","author":"Swerdlow","year":"2016","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.eclinm.2020.100280_bib0029","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.gastro.2018.05.022","article-title":"Variation in interleukin 6 receptor gene associates with risk of Crohn's disease and ulcerative colitis","volume":"155","author":"Parisinos","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eclinm.2020.100280_bib0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-Reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.eclinm.2020.100280_bib0031","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the canakinumab anti-inflammatory thrombosis outcomes study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.eclinm.2020.100280_bib0032","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3945\/ajcn.115.118216","article-title":"Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies","volume":"103","author":"Haycock","year":"2016","journal-title":"Am J Clin Nutr"}],"container-title":["EClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537020300249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537020300249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:00:52Z","timestamp":1762887652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537020300249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":32,"alternative-id":["S2589537020300249"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2020.100280","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study","name":"articletitle","label":"Article Title"},{"value":"EClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2020.100280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100280"}}